Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$20.04 USD
+0.05 (0.25%)
Updated May 7, 2024 10:02 AM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 1 - 20 ( 109 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Arcalyst Springing Forward; Abiprubart''s on the Clock
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Primed for Another Strong Year in RP; Waiting to See the River in RA
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Ruminating on KPL-404s Prospects in Rheumatoid Arthritis
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KNSA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Arcalyst Sees and Raises to the Top End; Looking For 404 in Q1
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Bigger, Faster, Better, More! Arcalyst Strong Q1; 2023 Guidance Increased
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
A Strong Close to 2022 for Arcalyst, Continued Growth Ahead
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Scores a Triple and Looks to Overseas Expansion
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D